These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 37895938)

  • 21. Lytic Phages against ST11 K47 Carbapenem-Resistant Klebsiella pneumoniae and the Corresponding Phage Resistance Mechanisms.
    Fang Q; Zong Z
    mSphere; 2022 Apr; 7(2):e0008022. PubMed ID: 35255715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isolation of bacteriophages against multidrug resistant
    Ghajavand H; Esfahani BN; Havaei A; Fazeli H; Jafari R; Moghim S
    Res Pharm Sci; 2017 Oct; 12(5):373-380. PubMed ID: 28974975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bacteriophages of Mycobacterium tuberculosis, their diversity, and potential therapeutic uses: a review.
    Zeynali Kelishomi F; Khanjani S; Fardsanei F; Saghi Sarabi H; Nikkhahi F; Dehghani B
    BMC Infect Dis; 2022 Dec; 22(1):957. PubMed ID: 36550444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of
    Tan D; Zhang Y; Cheng M; Le S; Gu J; Bao J; Qin J; Guo X; Zhu T
    Viruses; 2019 Nov; 11(11):. PubMed ID: 31752386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future.
    Łobocka M; Dąbrowska K; Górski A
    BioDrugs; 2021 May; 35(3):255-280. PubMed ID: 33881767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding and Exploiting Phage-Host Interactions.
    Stone E; Campbell K; Grant I; McAuliffe O
    Viruses; 2019 Jun; 11(6):. PubMed ID: 31216787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isolation and Characterization of Novel Lytic Phages Infecting Multidrug-Resistant Escherichia coli.
    Vera-Mansilla J; Sánchez P; Silva-Valenzuela CA; Molina-Quiroz RC
    Microbiol Spectr; 2022 Feb; 10(1):e0167821. PubMed ID: 35171030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mini review advantages and limitations of lytic phages compared with chemical antibiotics to combat bacterial infections.
    Guo Z; Yuan M; Chai J
    Heliyon; 2024 Jul; 10(14):e34849. PubMed ID: 39148970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Novel Bacteriophage with Broad Host Range against Clostridioides difficile Ribotype 078 Supports SlpA as the Likely Phage Receptor.
    Whittle MJ; Bilverstone TW; van Esveld RJ; Lücke AC; Lister MM; Kuehne SA; Minton NP
    Microbiol Spectr; 2022 Feb; 10(1):e0229521. PubMed ID: 35107319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Directed evolution of bacteriophages: impacts of prolific prophage.
    Peters TL; Schow J; Spencer E; Van Leuven JT; Wichman H; Miller C
    bioRxiv; 2024 Jun; ():. PubMed ID: 38979301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differentiation of polyvalent bacteriophages specific to uropathogenic Proteus mirabilis strains based on the host range pattern and RFLP.
    Maszewska A; Wójcik E; Ciurzyńska A; Wojtasik A; Piątkowska I; Dastych J; Różalski A
    Acta Biochim Pol; 2016; 63(2):303-10. PubMed ID: 26730411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Temperate Bacteriophages from Chronic Pseudomonas aeruginosa Lung Infections Show Disease-Specific Changes in Host Range and Modulate Antimicrobial Susceptibility.
    Tariq MA; Everest FLC; Cowley LA; Wright R; Holt GS; Ingram H; Duignan LAM; Nelson A; Lanyon CV; Perry A; Perry JD; Bourke S; Brockhurst MA; Bridge SH; De Soyza A; Smith DL
    mSystems; 2019 Jun; 4(4):. PubMed ID: 31164451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bacteriophage therapy for inhibition of multi drug-resistant uropathogenic bacteria: a narrative review.
    Chegini Z; Khoshbayan A; Vesal S; Moradabadi A; Hashemi A; Shariati A
    Ann Clin Microbiol Antimicrob; 2021 Apr; 20(1):30. PubMed ID: 33902597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy.
    Tagliaferri TL; Jansen M; Horz HP
    Front Cell Infect Microbiol; 2019; 9():22. PubMed ID: 30834237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens.
    Viertel TM; Ritter K; Horz HP
    J Antimicrob Chemother; 2014 Sep; 69(9):2326-36. PubMed ID: 24872344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phage Milagro: a platform for engineering a broad host range virulent phage for
    Yao G; Le T; Korn AM; Peterson HN; Liu M; Gonzalez CF; Gill JJ
    J Virol; 2023 Nov; 97(11):e0085023. PubMed ID: 37943040
    [No Abstract]   [Full Text] [Related]  

  • 37. Combination of genetically diverse Pseudomonas phages enhances the cocktail efficiency against bacteria.
    Naknaen A; Samernate T; Wannasrichan W; Surachat K; Nonejuie P; Chaikeeratisak V
    Sci Rep; 2023 Jun; 13(1):8921. PubMed ID: 37264114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. More's the Same-Multiple Hosts Do Not Select for Broader Host Range Phages.
    Myers J; Davis Ii J; Lollo M; Hudec G; Hyman P
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice.
    Vinodkumar CS; Kalsurmath S; Neelagund YF
    Indian J Pathol Microbiol; 2008; 51(3):360-6. PubMed ID: 18723958
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.